Multiple sclerosis (MS) patients who transitioned from natalizumab to...
Our news web pages include ground-breaking multiple sclerosis news and research from around the world.
These news stories are taken from external sources and as such, MS-UK does not verify, endorse or accept responsibility for their content.
Some of these pages have been written for medical professionals and this can be reflected in the complexity of language and content.
We’re here to support you, whether you are awaiting a diagnosis of multiple sclerosis or have been living with the condition for years.
Multiple sclerosis (MS) patients who transitioned from natalizumab to...
Smoking and doing little or no physical activity can affect multiple sclerosis (MS) progression. So...
A new study in Canadian Medical Association Journal (CMAJ) found no increased risk of autoimmune disorders in girls who received the human...
Evidence suggests people with non-relapsing progressive multiple sclerosis (PMS) may...
At its annual general meeting in Belfast the Royal College of Nursing voted in favour of a motion to decriminalise medical cannabis. The motion was raised by nurses in Suffolk, who feel that...
Researchers at the University of Geneva (UNIGE), Switzerland, and Geneva University Hospitals (HUG) have identified a DNA-binding factor called TOX that might play a role in triggering multiple...
In December 2017 the National Institute of Health and Care Excellence (NICE) announced a...
The US Food and Drug Administration has approved Gilenya (fingolimod) to treat relapsing multiple sclerosis (MS) in children and adolescents age 10 years and older. This is the first FDA approval...
A study by the University of Birmingham has...
According to a French study, the approved cancer drug rituximab, which...